FAILURE OF TRIMETHOPRIM-SULFAMETHOXAZOLE THERAPY IN EXPERIMENTAL ENTEROCOCCAL ENDOCARDITIS

To assess the potential efficacy of trimethoprim-sulfamethoxazole (TMP-SMX) against serious enterococcal infections, we used a rat enterococcal endocarditis model comparing TMP-SMX therapy (500 mg of TMP plus 2,500 mg of SMX per kg of body weight per day given every 8 h by intragastric gavage) with intravenous ampicillin therapy (1,000 mg/kg per day). Despite concentrations of active drug in serum well in excess of the MIC and MBC, the mean residual vegetation bacterial titer in TMP-SMX-treated rats was similar to that in untreated controls (8.4 ± 1.1 versus 8.6 ± 1.3 log10 CFU/g) and significantly higher than that in the ampicillin-treated group (3.6 ± 1.5 log10 CFU/g; P ≥ 0.001). This demonstrates discordance between in vitro activity and in vivo efficacy of TMP-SMX in serious enterococcal infection.